Mammalian cell population and medicaments for cell therapies in humans and improved cell cultivation methods
AssigneeSCARCELL Therapeutics
InventorsAntoine Lafont, Mathieu Castela
Life of this patent
Estimating the term…
Abstract
Compositions of matter, including cell populations and medicaments, are provided that are derived from human gingival fibroblasts and have cell phenotypes that occur in proportions not found in natural gum tissue, but rather, are preferentially are selected to express proteins favoring angiogenesis and anti-inflammatory effects, while reducing cell populations that promote tumorigenicity and/or formation of metalloproteinases that inhibit tissue regeneration. Methods of generating such compositions are provided that increase proliferation many-fold compared to previously known methods, and methods of using such compositions in a wide range of human cell therapies are provided.
Claims18
A pharmaceutical dose for treating a human ailment comprising:
- an injectable volume of about 1.0 ml to 2.5 ml containing:
- a medium comprising 10% dimethyl sulfoxide, 88% DMEM, and 1% non-essential amino acids;
- and
- between 2 and 40 million viable cultured human gingival fibroblast cells having phenotypes such that at least about 90% of the cell population expresses CD90 and CD63 and about 10% or less of the cell population expresses CD146,
- wherein the viable cultured human gingival fibroblast cells are cultured by a process comprising the steps of:
- obtaining a population of viable gingival fibroblast cells representative of naturally occurring gingival fibroblast cells in human gum tissue;
- culturing the viable gingival fibroblast cells through four passages in a culture medium that includes at least 20% fetal bovine serum (FBS) and basic fibroblast growth factor (bFGF), without isolating gingival fibroblast cell subpopulations, wherein during the first two passages, the population of viable gingival fibroblast cells monotonically increases;
- and
- culturing the viable gingival fibroblast cells to a fifth passage, wherein during the fifth passage, omitting the 20% FBS and bFGF from the culture medium and adding interleukin 1β in a concentration of 0.1 ng/ml to 10 ng/ml,
- wherein by completion of the fifth passage, the gingival fibroblast cells correspond to cell phenotypes cultivated so that at least about 90% of the cell population expresses CD90 and CD63 and about 10% or less of the cell population expresses CD146.
A pharmaceutical dose for treating a human ailment comprising:
- an injectable volume of about 1.0 ml to 2.5 ml containing:
- a medium comprising 10% dimethyl sulfoxide, 88% DMEM, and 1% non-essential amino acids;
- and
- at least 2 million viable cultured human gingival fibroblast cells having phenotypes such that at least about 90% of the cell population expresses CD90 and CD63 and about 10% or less of the cell population expresses CD146,
- wherein the viable cultured human gingival fibroblast cells are cultured by a process comprising the steps of:
- obtaining a population of viable gingival fibroblast cells representative of naturally occurring gingival fibroblast cells in human gum tissue;
- culturing the population of viable gingival fibroblast cells through four passages in a culture medium that includes at least 20% fetal bovine serum (FBS) and basic fibroblast growth factor (bFGF), without isolating gingival fibroblast cell subpopulations, wherein during the first two passages, the population of viable gingival fibroblast cells monotonically increases;
- and
- culturing the population of viable gingival fibroblast cells to a fifth passage, wherein during the fifth passage, omitting the 20% FBS and bFGF from the culture medium and adding interleukin 1β in a concentration of 0.1 ng/ml to 10 ng/ml and nonessential amino acids,
- wherein by completion of the fifth passage, the gingival fibroblast cells correspond to cell phenotypes cultivated so that at least about 90% of the cell population expresses CD90 and CD63 and about 10% or less of the cell population expresses CD146.
Dependencies are inferred from the claim text.